RecruitingNot applicableNCT06410300

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Checked against the public recordLast updated Jul 30, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations3
SponsorBo Lu
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Bo Lu
Interventions being studied
Radiation: Curative Radiotherapy; Drug: Immunotherapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Patient older than 18 years age * Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy. * Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible. * Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study. * ECOG performance status of 0-2 * Life expectancy of 6 months or longer * Patient able to provide a written informed consent prior to study entry Exclusion Criteria: * Prior thoracic radiotherapy to chest. * Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy. * Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Missouri - Ellis Fischel Cancer CenterColumbia, Missouri
  • Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey
  • University of Rochester Medical CenterRochester, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 30, 2026. Always confirm current availability with the study team.

View original record ↗